Krka Reports 14% Rise in Profits for Jan-Sept ‘21

By , 18 Nov 2021, 11:44 AM Business

Share this:

STA, 18 November 2021 - Drug maker Krka reported a group net profit of EUR 240.1 million for the first nine months of 2021, a year-on-year increase of 14% and the highest nine-month profit in the company's history, on the back of revenue that increased by 1% to EUR 1.18 billion.

Profit before income tax, depreciation and amortisation (EBITDA) was down by 8% to EUR 352.7 million, whereas pre-tax profit (EBIT) increased by 12% to EUR 271.3 million, shows the company's interim report released on Thursday.

Sales rose across all markets except Western Europe, where they declined by 13% due to fewer product launches and decreased use of medicines decreased due the COVID-19 pandemic.

In its key markets, in Central and Eastern Europe, sales rose by 4% and 5%, respectively. Sales in its largest single market, Russia, were flat in euro terms but rose by 14% in roubles.

Broken down by product category, sales of prescription drugs remained flat across the group, whereas sales of over-the-counter drugs rose by 8% and animal health products grew by 16%.

The group allocated EUR 45.3 million to investments in the first nine months of 2021, slightly less than in the same period last year, whereas overall R&D spending rose by 1% to EUR 113 million.

Chief executive Jože Colarič said the January-September figures were in accordance with expectations.

"We recorded the highest sales and net profit in the first nine months since incorporation. We maintained profitability at a high level and obtained marketing authorisations for 11 new products," he was quoted as saying.

The company's priorities remain to ensure sales growth, achieve higher-than-average sales growth in terms of market dynamics, and place among the leading branded generic pharmaceutical companies on individual markets and in selected therapeutic classes, he said.

Photo galleries and videos

This websie uses cookies. By continuing to browse the site you are agreeing to our use of cookies.